Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden

References

• McArdle A, Pennington S, FitzGerald O. Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs. Clin Rev Allergy Immunol. 2018; Dec55(3):271–294. doi: 10.1007/s12016-017-8630-7.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017; Mar 9376(10):957–970. doi: 10.1056/NEJMra1505557.
   PubMed Web of Science ®Google Scholar
• Exarchou S, Wallman J, Di Giuseppe D, et al. The national prevalence of clinically diagnosed psoriatic arthritis in Sweden 2017. J Rheumatol. 2023;50(6):781–788. doi: 10.3899/jrheum.221139.
   PubMed Web of Science ®Google Scholar
• Statistics Sweden. Official Statistics of Sweden: population: statistics Sweden; 2022 [cited 2023 28/07/2023]. Available from: https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START__BE/.
   Google Scholar
• Lindberg I, Lilja M, Geale K, et al. Incidence of psoriatic arthritis in patients with skin psoriasis and associated risk factors: a retrospective population-based cohort study in swedish routine clinical care. Acta Derm Venereol. 2020;100(18):adv00324. doi: 10.2340/00015555-3682.
   PubMedGoogle Scholar
• Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17(6):809–812.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford). 2003; 42(6):778–783. doi: 10.1093/rheumatology/keg217.
   PubMed Web of Science ®Google Scholar
• Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo J, et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30(4):245–250. doi: 10.1093/rheumatology/30.4.245.
   PubMedGoogle Scholar
• Coates LC, Orbai AM, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the psoriatic arthritis impact of disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173. doi: 10.1186/s12955-020-01422-z.
   PubMed Web of Science ®Google Scholar
• Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018; 14(5):405–417. doi: 10.1080/1744666X.2018.1468252.
   PubMed Web of Science ®Google Scholar
• Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(3):351–360.
   PubMed Web of Science ®Google Scholar
• Kennedy M, Papneja A, Thavaneswaran A, et al. Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis. Clin Exp Rheumatol. 2014;32(3):342–348.
   PubMed Web of Science ®Google Scholar
• Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460–1468. Decdoi: 10.1093/rheumatology/keg384.
   PubMed Web of Science ®Google Scholar
• Lofvendahl S, Petersson IF, Theander E, et al. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in Southern Sweden: is it all psoriasis-attributable morbidity? J Rheumatol. 2016;43(3):640–647. doi: 10.3899/jrheum.150406.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018; 391(10136):2285–2294. doi: 10.1016/S0140-6736(18)30949-8.
   PubMed Web of Science ®Google Scholar
• Swedish Rheumatology Association. Guidelines and recommendations: psoriatic arthritis – guidelines for drug treatment: Swedish Rheumatology Association; 2022 [cited 2023 28/07/2023]. Available from: https://riktlinjer.svenskreumatologi.se/riktlinjer-och-rekommendationer/psa/.
   Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):778–786. Jundoi: 10.1136/annrheumdis-2020-217163.
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532. doi: 10.1136/annrheumdis-2017-212127.
   PubMed Web of Science ®Google Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001. doi: 10.1111/bcp.13185.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Asahina A, Coates LC, et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023;401(10370):25–37. doi: 10.1016/S0140-6736(22)02302-9.
   PubMed Web of Science ®Google Scholar
• Merola JF, Landewe R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38–48. doi: 10.1016/S0140-6736(22)02303-0.
   PubMed Web of Science ®Google Scholar
• Coates LC, McInnes IB, Merola JF, et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: three-Year results from a phase IIb randomized controlled trial and its Open-Label extension study. Arthritis Rheumatol. 2022;74(12):1959–1970. Decdoi: 10.1002/art.42280.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Merola JF, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427–440. doi: 10.1016/S0140-6736(19)33161-7.
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). European public assessment reports: bimzelx. Procedure No. EMEA/H/C/005316/II/0011 European Medicines Agency 2023 [cited 2023 28/07/2023]. Available from: https://www.ema.europa.eu/en/documents/variation-report/bimzelx-h-c-5316-ii-0011-epar-assessment-report-variation_en.pdf.
   Google Scholar
• European Medicines Agency. Summary of product characteristics: bimzelx: european Medicines Agency; 2023 cited 2023 28/07/2023]. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf.
   Google Scholar
• Mease PJ, Gladman D, Merola JF, et al. SA64 Comparative Effectiveness of Bimekizumab in Patients with Psoriatic Arthritis: Results from a Systematic Literature Review and Network Meta-Analysis. Value Health. 2023;26(6).
   Google Scholar
• Mease PJ, McInnes I, Tam L, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60(5):2109–2121. doi: 10.1093/rheumatology/keab119.
   PubMed Web of Science ®Google Scholar
• Central European Bank. Average exchange rates - SEK to Euro 2022 [cited 2023 28/07/2023]. Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-sek.en.html.
   Google Scholar
• Turner HC, Lauer JA, Tran BX, et al. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019;22(9):1026–1032. Sepdoi: 10.1016/j.jval.2019.03.021.
   PubMed Web of Science ®Google Scholar
• Dental and Pharmaceutical Benefits Agency (TLV). Amendment to the Dental and Pharmaceutical Benefits Agency’s General Advice (TLVAR 2003:2) on Economic Evaluations; 2017 [cited 2023 Sep 20]. Available from: https://www.tlv.se/download/18.467926b615d084471ac3230c/1510316374332/TLVAR_2017_1.pdf
   Google Scholar
• Viollet J, O'Leary E, Camacho-Gonzalez C, et al. Willingness to pay for different severity levels in Sweden: an analysis of TLV decisions (2014-2022). Value in Health. 2022;25(12):S341. doi: 10.1016/j.jval.2022.09.1686.
   Web of Science ®Google Scholar
• Hansson-Hedblom A, Almond C, Borgstrom F, et al. Cost-effectiveness of ustekinumab in moderate to severe crohn’s disease in Sweden. Cost Eff Resour Alloc. 2018;16(1):28. doi: 10.1186/s12962-018-0114-y.
   PubMedGoogle Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351.
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-an ISPOR good research practices task force report. Value Health. 2015;18(2):161–172. doi: 10.1016/j.jval.2015.02.001.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. Technology appraisal guidance [TA711]. London (UK); 2021.
   Google Scholar
• Swedish Electronic Medicines Compendium (FASS). Drugs database: swedish Electronic Medicines Compendium (FASS); 2022 [cited 2023 28/07/2023]. Available from: https://www.fass.se/LIF/startpage.
   Google Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):i–xxi. 1–329. doi: 10.3310/hta15100.
   PubMed Web of Science ®Google Scholar
• Ali Y, Tom BD, Schentag CT, et al. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007;56(8):2708–2714. doi: 10.1002/art.22800.
   PubMedGoogle Scholar
• Chung CP, Thompson JL, Koch GG, et al. Are American college of rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis. 2006;65(12):1602–1607. doi: 10.1136/ard.2005.048975.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64 (Suppl 2):ii65–ii68. doi: 10.1136/ard.2004.031237.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Roseno NAL, Aagaard D, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs. Technology appraisal guidance (TA768). 2021. London, United Kingdom.
   Google Scholar
• Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125. doi: 10.1016/S0140-6736(20)30265-8.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–1136. doi: 10.1016/S0140-6736(20)30263-4.
   PubMed Web of Science ®Google Scholar
• Bravo Vergel Y, Hawkins NS, Claxton K, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford). 2007;46(11):1729–1735. doi: 10.1093/rheumatology/kem221.
   PubMed Web of Science ®Google Scholar
• Bojke L, Epstein D, Craig D, et al. Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 2011;50 Suppl 4:iv39–iv47. Sepdoi: 10.1093/rheumatology/ker245.
   PubMed Web of Science ®Google Scholar
• Cummins E, Asseburg C, Punekar YS, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health. 2011;14(1):15–23. Jandoi: 10.1016/j.jval.2010.10.016.
   PubMed Web of Science ®Google Scholar
• Burstrom K, Sun S, Gerdtham UG, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431–442. doi: 10.1007/s11136-013-0496-4.
   PubMed Web of Science ®Google Scholar
• Dental and Pharmaceutical Benefits Agency. (Tandvårds- och läkemedelsförmånsverket T. Price and decision database: dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket, TLV); 2022 [cited 2023 28/07/2023]. Available from: https://www.tlv.se/beslut/sok-priser-och-beslut-i-databasen.html.
   Google Scholar
• Region Stockolm and Gotland. Price list Contract drugs Region Stockholm and Region Gotland Region Stockolm and Gotland; 2022 [cited 2023 28/07/2023]. Available from: https://contracts.tendsign.com/ContractArea/Details/1579312?eId=2XwXmS0zykSquwLRsSricwA%3d.
   Google Scholar
• Wallman JK, Eriksson JK, Nilsson JA, et al. Costs in relation to disability, disease activity, and health-related quality of life in rheumatoid arthritis: observational data from Southern Sweden. J Rheumatol. 2016;43(7):1292–1299. doi: 10.3899/jrheum.150617.
   PubMed Web of Science ®Google Scholar
• Ekelund M, Mallbris L, Qvitzau S, et al. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis. Acta Derm Venereol. 2013;93(6):684–688. Novdoi: 10.2340/00015555-1591.
   PubMed Web of Science ®Google Scholar
• Södra sjukvårdsregionen. Regionala priser och ersättningar för södra sjukvårdsregionen: södra sjukvårdsregionen; 2022 [cited 2023 28/07/2023]. Available from: https://sodrasjukvardsregionen.se/download/regionala-priser-och-ersattningar-for-sodra-sjukvardsregionen-2022/?wpdmdl=24791&masterkey=61decc148fc78.
   Google Scholar
• D'Angiolella LS, Cortesi PA, Lafranconi A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: a systematic literature review. Pharmacoeconomics. 2018;36(5):567–589. Maydoi: 10.1007/s40273-018-0618-5.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Puolakka K, Bhattacharyya D, et al. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis: a finnish perspective. Cost Eff Resour Alloc. 2018;16(1):56. doi: 10.1186/s12962-018-0162-3.
   PubMedGoogle Scholar
• Schweikert B, Malmberg C, Akerborg O, et al. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate-to-Severe psoriasis in the UK. Pharmacoecon Open. 2020;4(4):635–648. Decdoi: 10.1007/s41669-020-00202-1.
   PubMed Web of Science ®Google Scholar
• Burton W, Morrison A, Maclean R, et al. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med. 2006;56(1):18–27. doi: 10.1093/occmed/kqi171.
   Google Scholar